Boston University researchers say they have developed a new, deadlier strain of COVID in the lab

U. S. regulators The U. S. centers have updated COVID-19 legal reinforcements, the first to directly target the common maximum omicron strain to date.

Researchers at Boston University say they have developed a new strain of COVID that has an 80% mortality rate following a series of similar experiments that would have first triggered the global pandemic that began in China.

The variant, a mixture of Omicron and the original virus in Wuhan, killed 80 percent of the inflamed mice, the university said. When the mice were exposed to Omicron, they had mild symptoms.

The studies were conducted through a team of scientists from Florida and Boston at the school’s National Laboratories for Emerging Infectious Diseases.

They extracted the spike protein from Omicron and attached it to the strain first detected at the beginning of the pandemic that began in Wuhan, China. They then documented the mice’s reaction to the hybrid strain.

“At home. . . mice, while Omicron causes a benign, non-fatal infection, the Omicron S carrier virus inflicts severe disease with an 80% mortality rate,” they wrote in a research paper.

The new strain has five times more infectious virus remnants than the Omicron variant, the researchers said.

Fox News contacted the university.

COVID-19 was first detected as coming from a rainy market in Wuhan, although most of the virus was conceived at the Wuhan Institute of Virology. The World Health Organization continues to face complaints over its handling of the crisis in its most important early stages.

The Omicron variant is highly transmissible, even in those who are fully vaccinated. The spike protein is responsible for infectivity rates, according to the researchers, in addition to other changes in the virus’ distribution and mortality.

A limitation to examine the breed of mice used, since other types are more similar to humans.

GET UPDATES ON THIS STORY ON FOXNEWS. COM

 

Leave a Comment

Your email address will not be published. Required fields are marked *